GCG and type 2 diabetes mellitus: Conversely, blockade of endogenous GLP-1 signaling by the GLP-1 receptor antagonist, exendin (9–39), diminishes the heart rate increase in response to intrajejunal glucose infusion in patients with T2DM (14).